Fragile X-associated disorders

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Fragile X-Associated Disorders Fragile X syndrome (FXS), also known as Martin-Bell syndrome, is the most common inherited cause of intellectual disability (ID), and it is the most common known single-gene cause of autism or autism spectrum disorders (ASDs). It is caused by a trinucleotide repeat (CGG) expansion at the 5′ noncoding region of the fragile X mental retardation 1 (FMR1) gene located on the long arm of the X chromosome at band Xq27.3. Large expansions (>200 CGG repeats) cause hypermethylation and silencing of the gene, leading to a loss of the gene product, fragile X mental retardation protein (FMRP). The resulting phenotype is complex and consists of cognitive impairments, difficulties with emotional and behavioral regulation, and certain physical characteristics as well, all elaborated upon later in this chapter. However, even smaller expansions (between 55 and 200 repeats) within the premutation range with normal or close-to-normal levels of FMRP can also result in clinical complications of its own. This is due in large part to the increased transcription of FMR1 mRNA seen in premutation carriers, which can be toxic to cells, particularly neurons and astrocytes. The resulting premutation-associated disorders are discussed at length in the second part of this chapter. Finally, pharmacological interventions that are still being studied are discussed. These pharmaceuticals, including mGluR5 antagonists and GABA agonists, seek to restore the imbalance of neurotransmission in FXS and have led to some promising preliminary results in mitigating or even reversing the neurobiological abnormalities caused by the loss of FMRP.

Original languageEnglish (US)
Title of host publicationNeuroscience in the 21st Century: From Basic to Clinical
PublisherSpringer New York
Pages2391-2410
Number of pages20
ISBN (Print)9781461419976, 1461419964, 9781461419969
DOIs
StatePublished - Nov 1 2013

Fingerprint

Fragile X Mental Retardation Protein
Fragile X Syndrome
Intellectual Disability
Trinucleotide Repeat Expansion
Genes
GABA Agonists
Poisons
X Chromosome
Gene Silencing
Autistic Disorder
Synaptic Transmission
Astrocytes
Reference Values
Pharmacology
Phenotype
Neurons
Messenger RNA
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Au, J., & Hagerman, R. J. (2013). Fragile X-associated disorders. In Neuroscience in the 21st Century: From Basic to Clinical (pp. 2391-2410). Springer New York. https://doi.org/10.1007/978-1-4614-1997-6_89

Fragile X-associated disorders. / Au, Jacky; Hagerman, Randi J.

Neuroscience in the 21st Century: From Basic to Clinical. Springer New York, 2013. p. 2391-2410.

Research output: Chapter in Book/Report/Conference proceedingChapter

Au, J & Hagerman, RJ 2013, Fragile X-associated disorders. in Neuroscience in the 21st Century: From Basic to Clinical. Springer New York, pp. 2391-2410. https://doi.org/10.1007/978-1-4614-1997-6_89
Au J, Hagerman RJ. Fragile X-associated disorders. In Neuroscience in the 21st Century: From Basic to Clinical. Springer New York. 2013. p. 2391-2410 https://doi.org/10.1007/978-1-4614-1997-6_89
Au, Jacky ; Hagerman, Randi J. / Fragile X-associated disorders. Neuroscience in the 21st Century: From Basic to Clinical. Springer New York, 2013. pp. 2391-2410
@inbook{70dcc05ec857491bb892022ce34c01f0,
title = "Fragile X-associated disorders",
abstract = "Fragile X-Associated Disorders Fragile X syndrome (FXS), also known as Martin-Bell syndrome, is the most common inherited cause of intellectual disability (ID), and it is the most common known single-gene cause of autism or autism spectrum disorders (ASDs). It is caused by a trinucleotide repeat (CGG) expansion at the 5′ noncoding region of the fragile X mental retardation 1 (FMR1) gene located on the long arm of the X chromosome at band Xq27.3. Large expansions (>200 CGG repeats) cause hypermethylation and silencing of the gene, leading to a loss of the gene product, fragile X mental retardation protein (FMRP). The resulting phenotype is complex and consists of cognitive impairments, difficulties with emotional and behavioral regulation, and certain physical characteristics as well, all elaborated upon later in this chapter. However, even smaller expansions (between 55 and 200 repeats) within the premutation range with normal or close-to-normal levels of FMRP can also result in clinical complications of its own. This is due in large part to the increased transcription of FMR1 mRNA seen in premutation carriers, which can be toxic to cells, particularly neurons and astrocytes. The resulting premutation-associated disorders are discussed at length in the second part of this chapter. Finally, pharmacological interventions that are still being studied are discussed. These pharmaceuticals, including mGluR5 antagonists and GABA agonists, seek to restore the imbalance of neurotransmission in FXS and have led to some promising preliminary results in mitigating or even reversing the neurobiological abnormalities caused by the loss of FMRP.",
author = "Jacky Au and Hagerman, {Randi J}",
year = "2013",
month = "11",
day = "1",
doi = "10.1007/978-1-4614-1997-6_89",
language = "English (US)",
isbn = "9781461419976",
pages = "2391--2410",
booktitle = "Neuroscience in the 21st Century: From Basic to Clinical",
publisher = "Springer New York",

}

TY - CHAP

T1 - Fragile X-associated disorders

AU - Au, Jacky

AU - Hagerman, Randi J

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Fragile X-Associated Disorders Fragile X syndrome (FXS), also known as Martin-Bell syndrome, is the most common inherited cause of intellectual disability (ID), and it is the most common known single-gene cause of autism or autism spectrum disorders (ASDs). It is caused by a trinucleotide repeat (CGG) expansion at the 5′ noncoding region of the fragile X mental retardation 1 (FMR1) gene located on the long arm of the X chromosome at band Xq27.3. Large expansions (>200 CGG repeats) cause hypermethylation and silencing of the gene, leading to a loss of the gene product, fragile X mental retardation protein (FMRP). The resulting phenotype is complex and consists of cognitive impairments, difficulties with emotional and behavioral regulation, and certain physical characteristics as well, all elaborated upon later in this chapter. However, even smaller expansions (between 55 and 200 repeats) within the premutation range with normal or close-to-normal levels of FMRP can also result in clinical complications of its own. This is due in large part to the increased transcription of FMR1 mRNA seen in premutation carriers, which can be toxic to cells, particularly neurons and astrocytes. The resulting premutation-associated disorders are discussed at length in the second part of this chapter. Finally, pharmacological interventions that are still being studied are discussed. These pharmaceuticals, including mGluR5 antagonists and GABA agonists, seek to restore the imbalance of neurotransmission in FXS and have led to some promising preliminary results in mitigating or even reversing the neurobiological abnormalities caused by the loss of FMRP.

AB - Fragile X-Associated Disorders Fragile X syndrome (FXS), also known as Martin-Bell syndrome, is the most common inherited cause of intellectual disability (ID), and it is the most common known single-gene cause of autism or autism spectrum disorders (ASDs). It is caused by a trinucleotide repeat (CGG) expansion at the 5′ noncoding region of the fragile X mental retardation 1 (FMR1) gene located on the long arm of the X chromosome at band Xq27.3. Large expansions (>200 CGG repeats) cause hypermethylation and silencing of the gene, leading to a loss of the gene product, fragile X mental retardation protein (FMRP). The resulting phenotype is complex and consists of cognitive impairments, difficulties with emotional and behavioral regulation, and certain physical characteristics as well, all elaborated upon later in this chapter. However, even smaller expansions (between 55 and 200 repeats) within the premutation range with normal or close-to-normal levels of FMRP can also result in clinical complications of its own. This is due in large part to the increased transcription of FMR1 mRNA seen in premutation carriers, which can be toxic to cells, particularly neurons and astrocytes. The resulting premutation-associated disorders are discussed at length in the second part of this chapter. Finally, pharmacological interventions that are still being studied are discussed. These pharmaceuticals, including mGluR5 antagonists and GABA agonists, seek to restore the imbalance of neurotransmission in FXS and have led to some promising preliminary results in mitigating or even reversing the neurobiological abnormalities caused by the loss of FMRP.

UR - http://www.scopus.com/inward/record.url?scp=84929295279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929295279&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-1997-6_89

DO - 10.1007/978-1-4614-1997-6_89

M3 - Chapter

SN - 9781461419976

SN - 1461419964

SN - 9781461419969

SP - 2391

EP - 2410

BT - Neuroscience in the 21st Century: From Basic to Clinical

PB - Springer New York

ER -